A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

NCT05469178 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Bemcentinib
DRUG: Pembrolizumab
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

BerGenBio ASA